Applying Evidence-Based Medicine Standards to Digital Tools

Abstract

This article argues that clinicians and researchers must apply the same evidence-based medicine (EBM) hierarchy to digital health interventions that they use for traditional treatments. When comparing interventions for the same clinical indication, evidentiary standards should not change based on delivery method - whether pharmacotherapy, psychotherapy, or digital therapeutics. The manuscript outlines the spectrum of digital health tools (Digital Health, Digital Medicine, and Digital Therapeutics) and examines the rigorous FDA approval process for digital therapeutics, which requires Phase III randomized controlled trials comparable to pharmaceutical standards. Using substance use disorder treatment as a concrete example, the article demonstrates the “evidence gap” between FDA-approved digital therapeutics with robust clinical trial data and unvalidated commercial apps that rely on testimonials or no published research. The framework extends to emerging artificial intelligence applications in therapeutic spaces. Finally, the article addresses systemic implementation barriers - including reimbursement uncertainty, limited provider awareness, and clinical workflow integration challenges - and practical considerations clinicians face when selecting digital tools, including cost-access trade-offs, engagement metrics, and professional liability concerns.